WO2021194953A1 - Procédé de traitement de sujets résistants à l'inhibiteur de l'idh1 - Google Patents

Procédé de traitement de sujets résistants à l'inhibiteur de l'idh1 Download PDF

Info

Publication number
WO2021194953A1
WO2021194953A1 PCT/US2021/023452 US2021023452W WO2021194953A1 WO 2021194953 A1 WO2021194953 A1 WO 2021194953A1 US 2021023452 W US2021023452 W US 2021023452W WO 2021194953 A1 WO2021194953 A1 WO 2021194953A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
cancer
ethyl
idhl
pharmaceutically acceptable
Prior art date
Application number
PCT/US2021/023452
Other languages
English (en)
Inventor
Nathan Arthur BROOKS
Raymond Gilmour
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Priority to EP21718411.8A priority Critical patent/EP4125916B1/fr
Priority to AU2021241471A priority patent/AU2021241471B2/en
Priority to CA3172679A priority patent/CA3172679A1/fr
Priority to CN202180023934.5A priority patent/CN115335059A/zh
Priority to IL296094A priority patent/IL296094A/en
Priority to MX2022011846A priority patent/MX2022011846A/es
Priority to US17/911,746 priority patent/US20230071978A1/en
Priority to KR1020227036322A priority patent/KR20220155379A/ko
Priority to BR112022017491A priority patent/BR112022017491A2/pt
Priority to JP2022557868A priority patent/JP7462789B2/ja
Publication of WO2021194953A1 publication Critical patent/WO2021194953A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Definitions

  • the present invention relates to the treatment of cancer in subjects with a mutant isocitrate dehydrogenase 1 (IDHl) inhibitor disclosed herein.
  • IDHl isocitrate dehydrogenase 1
  • IDH1 is an enzyme that catalyzes the conversion of isocitrate to a-ketoglutarate (a -KG) and reduces nicotinamide adenine dinucleotide phosphate (NADP + ) to NADPH (Megias-Vericat J, et al ., Blood Lymph. Cancer: Targets and Therapy 2019; 9: 19-32).
  • Neomorphic (de novo) mutations in IDHl e.g, at IDHl amino acid residue R132, contribute to tumorigenesis in several types of cancer, including solid tumors and hematologic malignancies (Badur MG, et al ., Cell Reports 2018; 25: 1680).
  • IDHl mutations can result in high levels of 2-hydroxyglutarate (2-HG), which inhibits cellular differentiation, and inhibitors of mutant IDHl can reduce 2-HG levels, which promotes cellular differentiation (Molenaar RJ, et al., Oncogene 2018; 37: 1949-1960).
  • AML acute myeloid leukemia
  • AML acute myeloid leukemia
  • Induction chemotherapy with cytarabine and an anthracy cline (“7 + 3”) has been the standard of care for more than 4 decades for subjects with newly diagnosed AML.
  • five drugs have been approved by the U.S. Food and Drug Administration for treating AML: midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin (Bloomfield CD, et al., Blood Revs. 2018; 32: 416-425), and ivosidenib (Megias-Vericat J, et al ., Blood Lymph. Cancer: Targets and Therapy 2019; 9: 19-32).
  • IDHl resistance mutations are observed in 7-14% of AML subjects, and the associated high 2-HG level can result in an epigenetic hyper-methylation phenotype and a block in differentiation, resulting in leukemogenesis (Megias-Vericat J, et al., Blood Lymph. Cancer: Targets and Therapy 2019; 9: 19-3).
  • mutations in the Flt3 kinase are observed in approximately one third of AML subjects (Lee HJ, et al., Oncotarget 2018; 9: 924-936).
  • So called “secondary” IDHl mutations may contribute to relapse after treatment with a mutant IDHl inhibitor.
  • R119P G131 A, D279N, S280F, G289D orH315D
  • Molecular mechanisms mediating relates following ivosidenib monotherapy in subjects with IDHl -mutant relapsed or refractory acute myeloid leukemia,” 61 st Am. Soc. Hematol. (ASH) Annual Meeting poster , Dec. 7-10, 2019, Orlando, FL, USA; Choe, S., et al., Blood Adv. 2020, 4(9): 1894-1905).
  • mutant IDHl inhibitors are disclosed in WO 2018/111707 Al, including a compound defined herein as “Compound A,” which is a covalent inhibitor of mutant IDHl that modifies a single cysteine (Cys269) in an allosteric binding pocket, rapidly inactivates the enzyme, and selectively inhibits 2-HG production, without affecting a-KG levels (WO 2018/111707 Al).
  • the present invention provides a method for treating cancer, comprising administering to a human cancer subject having an IDHl R132 mutation and one or more secondary IDHl mutations a therapeutically effective amount of a compound of the Formula I:
  • R 1 is -CH 2 CH(CH )2, -CH2CH3, -CH2CH2OCH3, or -CHz-cyclopropyl;
  • R 2 is -CH3 or -CH2CH3; and
  • X is N or CH; or a pharmaceutically acceptable salt thereof.
  • X is N, or a pharmaceutically acceptable salt thereof.
  • X is N
  • R 1 is -CFh-cyclopropyl
  • R 2 is -CH 2 CH 3 , or a pharmaceutically acceptable salt thereof.
  • X is N
  • R 1 is -CFh-cyclopropyl
  • R 2 is -CH 2 CH 3.
  • the compound of Formula I is:
  • the compound of Formula I is 7-[[(lS)-l-[4-[(lS)-2- cyclopropyl-l-(4-prop-2-enoylpiperazin-l-yl)ethyl]phenyl]ethyl]amino]-l-ethyl-4H- pyrimido[4,5-d][l,3]oxazin-2-one.
  • the compound of Formula I is:
  • Compound A (referred to herein as “Compound A”), or a pharmaceutically acceptable salt thereof.
  • the compound is Compound A.
  • the R132 mutation is R132H. In another embodiment, the IDHl mutation is R132C. In another embodiment, the IDHl mutation is R132G. In another embodiment, the IDHl mutation is R132L. In another embodiment, the IDHl mutation is R132S.
  • the one or more secondary IDHl mutations is one or more of R119P, G131 A, D279N, S280F, G289D or H315D.
  • the secondary IDH1 mutation is two or more of R119P, G131 A, D279N, S280F, G289D orH315D.
  • the subject is identified as having an R132 IDHl mutation. In another embodiment, the subject is identified as having an R132 IDHl mutation in tissue.
  • the subject is identified as having one or more secondary IDHl mutations.
  • the cancer is a hematologic malignancy, and the subject is identified as having an R132 IDHl mutation in blood, bone marrow, lymph node or lymphatic fluid. In another embodiment, the subject is identified as having an R132 IDHl mutation in blood cells, bone marrow cells, or blood cells, or lymph node cells, or lymphatic fluid cells. In another embodiment, the subject is identified as having one or more secondary IDHl mutations.
  • the cancer is a solid tumor cancer, and the subject is identified as having an R132 IDHl mutation in solid tumor tissue.
  • the solid tumor tissue is cholangiocarcinoma tissue.
  • the subject is identified as having an R132 IDHl mutation in solid tumor tissue cells.
  • the subject is identified as having one or more secondary IDHl mutations.
  • the cancer is a solid tumor.
  • the solid tumor is cholangiocarcinoma, head & neck cancer, chondrosarcoma, hepatocellular carcinoma, melanoma, pancreatic cancer, astrocytoma, oligodendroglioma, glioma, glioblastoma, bladder carcinoma, colorectal cancer, lung cancer, or sinonasal undifferentiated carcinoma.
  • the lung cancer is non-small cell lung cancer.
  • the solid tumor is cholangiocarcinoma.
  • the cancer is a hematologic malignancy.
  • the hematologic malignancy is acute myeloid leukemia, myelodysplastic syndrome myeloproliferative neoplasm, angioimmunoblastic T-cell lymphoma, T-cell acute lymphoblastic leukemia, polycythemia vera, essential thrombocythemia, primary myelofibrosis or chronic myelogenous leukemia.
  • the hematologic malignancy is acute myeloid leukemia.
  • the subject had been treated with a mutant IDHl inhibitor other than a compound of Formula I.
  • the mutant IDHl inhibitor other than a compound of Formula I is vorasidenib, BAY-1436032, AGI-5198, IDH305, or ivosidenib.
  • the mutant IDHl inhibitor other than a compound of Formula I is ivosidenib.
  • the subject had been treated with a mutant IDHl inhibitor other than a compound of Formula I prior to treatment with a compound of Formula I.
  • the present invention also provides a compound of Formula I:
  • R 1 is -CH 2 CH(CH )2, -CH2CH3, -CH2CH2OCH3, or -CHz-cyclopropyl;
  • R 2 is -CH 3 or -CH 2 CH 3 ;
  • X is N or CH; or a pharmaceutically acceptable salt thereof; for use in treating cancer in a human subject having an IDHl R132 mutation and one or more secondary IDHl mutations.
  • X is N, or a pharmaceutically acceptable salt thereof; it is preferred thatR 1 is -CH2-cyclopropyl, or a pharmaceutically acceptable salt thereof; it is preferred that R 2 is -CH2CH3, or a pharmaceutically acceptable salt thereof; it is more preferred that X is N, R 1 is -CH2-cyclopropyl, and R 2 is -CH2CH3, or a pharmaceutically acceptable salt thereof; it is most preferred that X is N, R 1 is -CH2-cyclopropyl, and R 2 is -CH2CH3.
  • Preferred compounds of Formula I are:
  • a more preferred compound of Formula I is:
  • the cancer is relapsed cancer.
  • the relapsed cancer is a solid tumor cancer.
  • the relapsed solid tumor cancer is cholangiocarcinoma.
  • the relapsed cancer is hematologic malignancy.
  • the relapsed hematologic malignancy is relapsed AML.
  • the cancer is refractory cancer.
  • the refractory cancer is a solid tumor cancer.
  • the refractory solid tumor cancer is cholangiocarcinoma.
  • the refractory cancer is hematologic malignancy.
  • the refractory hematologic malignancy is refractory AML.
  • the cancer is advanced cancer.
  • the advanced cancer is an advanced solid tumor cancer.
  • the advanced solid tumor cancer is cholangiocarcinoma.
  • the advanced cancer is an advanced hematologic malignancy.
  • the advanced hematologic malignancy is advanced AML.
  • the AML is acute promyelocytic leukemia.
  • hematologic tissue refers to blood, bone marrow, spleen, lymph node, or lymphatic fluid.
  • solid tumor tissue refers to tissue that is not hematologic tissue.
  • Non limiting examples of solid tissue are cholangial tissue, pancreatic tissue, head tissue, neck tissue, hepatic tissue, skin tissue, astrocytomal tissue, oligodendroglial tissue, glial tissue, brain tissue, bladder tissue, colorectal tissue, lung tissue, and sinonasal undifferentiated carcinoma.
  • solid tumor cancer means that the cancer originated in a tissue that is not blood, bone marrow, lymph node or lymphatic fluid.
  • hematologic malignancy relates to cancer that in the blood, the bone marrow, the lymph node or the lymphatic fluid.
  • advanced hematological malignancy refers to malignancy that has spread to lymph nodes or to other tissues outside of the blood or the bone marrow.
  • cancer subject means a subject who has been diagnosed with cancer.
  • refractory cancer refers to cancer that has been treated, but the human cancer subject did not respond to treatment.
  • relapsed cancer means that the human cancer subject responded to treatment for a period of time, but that the cancer has reoccurred.
  • advanced cancer refers to cancer that has spread to lymph nodes or to other tissues outside of the cancer’s point of origin.
  • advanced acute myeloid leukemia is acute myeloid leukemia that has spread to a tissue outside of the blood or the bone marrow.
  • solid tumor subject means a subject who has been diagnosed with a solid tumor cancer.
  • the solid tumor cancer is cholangiocarcinoma.
  • hematologic malignancy subject means a subject who has been diagnosed with a hematologic malignancy.
  • the hematologic malignancy subject is an AML subject.
  • AML subject means a subject who has been diagnosed with AML. Methods for diagnosing AML are known to those of ordinary skill in the art, e.g ., in Dohner H, el al ., Blood 2017 ; 129: 424-447.
  • hematologic malignancy e.g, AML
  • AML hematologic malignancy
  • hematologic recovery includes improvement in overall survival, partial response, long-term stable disease, or improvement in long-term survival characterized as complete remission (determined by less than 5% myeloblasts in bone marrow, the absence of circulating blasts, hematologic recovery (as evidenced by a peripheral blood absolute neutrophil count greater than 1,000 cells/ pL and a platelet count greater than 100,000/pL, without the need for red blood cell transfusion, and the absence of extramedullary disease) (Bloomfield CD, etal., Blood Revs. 2018 ; 32: 416-425).
  • IDHl R132 mutation refers to an IDHl mutation at amino acid residue 132 in a subject’s IDHl gene, as determined, e.g, in the subject’s nucleic acid (e.g, DNA). As used herein, an “IDHl R132 mutation” is not a “secondary IDHl mutation.”
  • secondary IDHl mutation refers to an IDHl mutation that occurs in the IDHl enzyme in a human subject after treatment with a mutant IDHl inhibitor other than a compound of Formula I herein.
  • the one or more secondary IDHl mutations is one or more of R119P, G131 A, D279N, S280F, G289D or H315D in IDHl.
  • other secondary IDHl mutations may be reported in the future.
  • a “secondary IDHl mutation” is not an “IDHl R132 mutation.”
  • mutant IDHl inhibitor refers to a compound that inhibits the enzyme activity of and/or the production of 2-HG by a mutant IDHl enzyme. Methods for assaying mutant IDHl enzyme activity are known to those of ordinary skill in the art, e.g, in WO 2018/111707 Al. In the term “mutant IDHl inhibitor, the word “mutant” refers to the IDHl gene, not the inhibitor.
  • the term “identified as having an IDHl R132 mutation” means that nucleic acid (e.g, DNA) from a human subject’s tissue or cells has been analyzed to determine if the human subject has an IDHl R132 mutation.
  • one or more of the human subject’s blood cells, bone marrow cells, lymph node, lymph node cells, lymphatic fluid or lymphatic fluid cells has been analyzed for an IDHl R132 mutation.
  • the human subject’s solid tissue has been analyzed for an IDHl R132 mutation.
  • the party who identifies the human subject as having an IDHl R132 mutation can be different than the party that administers the compound.
  • the party who identifies the human subject as having an IDHl R132 mutation is different than the party that administers the compound.
  • nucleic acid e.g ., DNA
  • a human subject has one or more secondary IDHl mutation(s).
  • Analytical methods for identifying genetic mutations are known to those of ordinary skill in the art (Clark, O., etal, Clin. Cancer. Res. 2016 ; 22: 1837-42), including, but not limited to, karyotyping (Guller JL, et al., J. Mol. Diagn. 2010; 12: 3- 16), fluorescence in situ hybridization (Yeung DT, et al. , Pathology 2011; 43: 566-579), Sanger sequencing (Lutha, R et al.
  • treatment are meant to include slowing, stopping, or reversing the progression of cancer. These terms also include alleviating, ameliorating, attenuating, eliminating, or reducing one or more symptoms of a disorder or condition, even if the cancer is not actually eliminated and even if progression of the cancer is not itself slowed, stopped or reversed.
  • “Therapeutically effective amount” means the amount of a compound, or pharmaceutically acceptable salt thereof, administered to the subject that will elicit the biological or medical response of or desired therapeutic effect on a subject.
  • a therapeutically effective amount can be readily determined by the attending clinician, as one skilled in the art, by the use of known techniques and by observing results obtained under analogous circumstances.
  • determining the effective amount for a subject a number of factors are considered by the attending clinician, including, but not limited to: size, age, and general health of the subject; the specific disease or disorder involved; the degree of or involvement or the severity of the disease or disorder; the response of the individual subject; the particular compound administered; the mode of administration; the bioavailability characteristics of the preparation administered; the dose regimen selected; the use of concomitant medication; and other relevant circumstances.
  • a compound of Formula I herein can optionally be formulated as a pharmaceutical composition administered by any route which makes the compound bioavailable, including oral, intravenous, and transdermal routes. It is preferred that such compositions are formulated for oral administration.
  • Such pharmaceutical compositions and processes for preparing same are well known in the art. (See, e.g., Remington: The Science and Practice of Pharmacy (D.B. Troy, Editor, 21st Edition, Lippincott, Williams & Wilkins, 2006).
  • a "pharmaceutically acceptable carrier, diluent, or excipient” is a medium generally accepted in the art for the delivery of biologically active agents to mammals, e.g., humans.
  • compounds administered in the method of the invention are capable of forming salts.
  • the compounds react with any of a number of inorganic and organic acids to form pharmaceutically acceptable acid addition salts.
  • Such pharmaceutically acceptable acid addition salts and common methodology for preparing them are well known in the art. See, e.g., P. Stahl, et al., HANDBOOK OF PHARMACEUTICAL SALTS: PROPERTIES, SELECTION AND USE, (VCHA/Wiley-VCH, 2008).
  • “Pharmaceutically acceptable salts” or “a pharmaceutically acceptable salt” refers to the relatively non-toxic, inorganic and organic salt or salts of the compounds of the present invention (S.M. Berge, etal., “Pharmaceutical Salts”, Journal of Pharmaceutical Sciences, Vol 66, No. 1, January 1977).
  • Ivosidenib and Compound A are prepared as a 20 mM stock in 100% DMSO (dimethyl sulfoxide) (Sigma, D2438) and diluted serially in 100% DMSO to achieve the desired concentrations. DMSO preps are further diluted with cell culture media prior to addition in the assay. Cell lines. U-87 MG cells (ATCC, HTB-14) are cultured and assayed in MEM (Gibco, 11095) with 2 mM GlutaMAX (Gibco, 35050), 1 mM Pyruvate (Gibco, 11360),
  • 0.1 mM NEAA (Non-essential amino acid) Gibco, 11140) and 10% dialyzed FBS (Fetal bovine serum) (Gibco, 26400).
  • Ba/F3 cells (DSMZ, ACC 300) are cultured and assayed in RPMI 1640 (Gibco, 22400) with 10% heat inactivated FBS (Gibco, 10082-147) and 10 ng/ml mouse IL3 (R&D systems, 403-ML-025).
  • Cell-based inhibition assays are performed by measuring 2- HG in either U-87 MG cells or Ba/F3 cells in which IDH mutations are expressed.
  • DNA constructs encoding IDH1 mutations are introduced into U-87 MG cells using transfection (Promega FuGENE HD, E2311) or lentiviral transduction, and the IDH-mutant expressing cell lines are selected using blasticidin (5 pg/ml) or puromycin (1 pg/ml).
  • 20,000-50,000 cells per well are plated in 96 well cell culture plates (Falcon, 353377) 2hrs prior to treatment. Cells are treated with serial dilutions of compound A in standard growth media. Plates are incubated in a mammalian cell culture incubator (humidified, 37°C, 5%CO?) for 16-72 hrs.
  • the media is aspirated and cell lysates are prepared either by addition of 30 pL/well lysis buffer (25 mM Tris-HCl pH7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton-X 100, 2X Halt protease + phosphatase inhibitor (Pierce, 78441) (for derivatization LC-MS method) or by addition of 100 pL 80% methanol/20% water containing LC-MS internal standards (1 mM 13 C 4 a-KG/ 13 Cs 2-HG) per well (for ion pairing LC-MS method). 96-well sample plates are then sealed, shaken at 450 rpm for 10 min, and then placed at -20°C and stored until LC-MS analysis.
  • 30 pL/well lysis buffer 25 mM Tris-HCl pH7.5
  • 150 mM NaCl 150 mM NaCl
  • 1 mM EDTA 1 m
  • Ba/F3 cells are transfected with DNA constructs encoding IDHlR132H-myc, IDHlR132H_S280F-myc, or IDHlR132C_S280F-myc constructs using NEON Transfection system (Life Technologies, MPK10025) and isolated using Puromycin (2 pg/mL) or Blasticidin (10 pg/mL). Stably transfected lines are used for inhibitor assays. 15,000 Ba/F3 cells per well are plated in 96 well cell culture plates (Falcon, 353377) 2 hours prior to treatment. Cells are treated with serial dilutions of the desired compounds in standard growth media.
  • Plates are incubated in a mammalian cell culture incubator (humidified, 37 °C, 5% CO2) for the desired time (72 or 96 hours). Following the incubation period, conditioned media from each well is collected for 2-HG analysis by LC-MS.
  • a mammalian cell culture incubator humidity, 37 °C, 5% CO2
  • LC-MS metabolite analysis of conditioned media and cell lysates The effect of inhibitors on the concentrations of 2-HG are determined by liquid chromatography- mass spectrometry (LC-MS) analysis of cell lysates or conditioned media using either a derivatization method or an ion-pairing method as described below.
  • LC-MS liquid chromatography- mass spectrometry
  • calibration curves are prepared by spiking 2-HG and a-KG into cell culture media and cell lysis buffer respectively.
  • the method utilizes derivatization with O-benzylhydroxylamine prior to analysis by LC-MS.
  • 10 pL of each standard or sample (media or cell extract) is placed into a deep-well 96-well plate and combined with 100 pL of internal standard solution containing 10 pM d5-3- hydroxyglutarate and 10 pM d6-a-KG.
  • 220 pL of the upper layer is transferred to a new 96-well plate.
  • Samples are dried under heated nitrogen at 50 °C and reconstituted with 100 pL of methanol/water (1 : 1).
  • 1 pL of derivatized sample is injected onto an LC-MS system consisting of a Shimadzu Prominence 20A HPLC system and a Thermo Quantum UltraTM triple quadrupole mass spectrometer. Analytes are separated on a Water XBridgeTM Cl 8 column (2.1 x 50 mm, 3.5 pm) with a flow rate of 0.6 mL/minute.
  • Mobile phase A is 0.1% formic acid in water and mobile phase B is methanol.
  • the gradient profile is: 0 minutes, 5% B; 2 minutes, 100% B; 4.00 minutes, 100% B; 4.1 minutes, 5% B; 5.50 minutes, stop.
  • the mass spectrometer utilizes a HESI-II probe operated in positive ion selected reaction monitoring mode.
  • Calibration curves are constructed by plotting analyte concentrations vs. analyte/internal standard peak area ratios and performing a quadratic fit of the data using a 1/concentration weighting with XcaliburTM software. Analyte concentrations for the unknowns are back calculated from the calibration curves.
  • the extracts are chromatographically resolved using a Hypercarb column, 2.1x20 mm, 5.0 mm Javelin HTS (Thermo Scientific, PN: 35005-022135).
  • Mobile phase A is water/lOmM tributylamine/15mM acetic acid.
  • Mobile phase B is acetonitrile/20mM tributylamine/30mM acetic acid.
  • the solvent flow rate is 1.0 mL/min.
  • the isocratic condition is kept at 26% mobile phase B.
  • the valve, sample loop, and needle are washed with 50% acetonitrile: 50% methanol for 20 seconds.
  • the column temperature is kept at 55°C.
  • Calibration curves are calculated by least-square linear regression with 1/x weighting. 2-HG and a-KG are quantified using standard curve and ratio of the peak area of analytes to internal standard. Data analysis is performed using Multi Quant 3.0 (AB Sciex). The raw data are exported to Excel spreadsheets
  • IC50 Curves for each compound are obtained using four parameter data fitting analysis in GraphP ad/Prism software.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

La présente invention concerne le traitement de sujets atteints d'un cancer humain avec un inhibiteur mutant d'isocitrate déshydrogénase 1 de formule I.
PCT/US2021/023452 2020-03-23 2021-03-22 Procédé de traitement de sujets résistants à l'inhibiteur de l'idh1 WO2021194953A1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EP21718411.8A EP4125916B1 (fr) 2020-03-23 2021-03-22 Procédé de traitement de sujets résistants à l'inhibiteur de l'idh1
AU2021241471A AU2021241471B2 (en) 2020-03-23 2021-03-22 Method for treating IDH1 inhibitor-resistant subjects
CA3172679A CA3172679A1 (fr) 2020-03-23 2021-03-22 Utilisation de composes de 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazine-2-one pour traiter des sujets resistants aux inhibiteurs d'idh1
CN202180023934.5A CN115335059A (zh) 2020-03-23 2021-03-22 用于治疗idh1抑制剂抗性受试者的方法
IL296094A IL296094A (en) 2020-03-23 2021-03-22 A method for treating subjects resistant to idh1 inhibitors
MX2022011846A MX2022011846A (es) 2020-03-23 2021-03-22 Metodo para el tratamiento de sujetos resistentes al inhibidor idh1.
US17/911,746 US20230071978A1 (en) 2020-03-23 2021-03-22 Method for treating idh1 inhibitor-resistant subjects
KR1020227036322A KR20220155379A (ko) 2020-03-23 2021-03-22 Idh1 억제제-저항성 대상체를 치료하는 방법
BR112022017491A BR112022017491A2 (pt) 2020-03-23 2021-03-22 Método para tratar indivíduos resistentes ao inibidor idh1
JP2022557868A JP7462789B2 (ja) 2020-03-23 2021-03-22 Ｉｄｈ１阻害剤耐性対象の治療方法

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202062993135P 2020-03-23 2020-03-23
US62/993,135 2020-03-23
US202063024761P 2020-05-14 2020-05-14
US63/024,761 2020-05-14
US202163151905P 2021-02-22 2021-02-22
US63/151,905 2021-02-22

Publications (1)

Publication Number Publication Date
WO2021194953A1 true WO2021194953A1 (fr) 2021-09-30

Family

ID=75478297

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/023452 WO2021194953A1 (fr) 2020-03-23 2021-03-22 Procédé de traitement de sujets résistants à l'inhibiteur de l'idh1

Country Status (11)

Country Link
US (1) US20230071978A1 (fr)
EP (1) EP4125916B1 (fr)
JP (1) JP7462789B2 (fr)
KR (1) KR20220155379A (fr)
CN (1) CN115335059A (fr)
AU (1) AU2021241471B2 (fr)
BR (1) BR112022017491A2 (fr)
CA (1) CA3172679A1 (fr)
IL (1) IL296094A (fr)
MX (1) MX2022011846A (fr)
WO (1) WO2021194953A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022020281A1 (fr) * 2020-07-20 2022-01-27 Eli Lilly And Company Polythérapie avec un inhibiteur d'idh1 mutant, un analogue de désoxyadénosine et un agent à base de platine
US11746115B2 (en) 2021-08-13 2023-09-05 Eli Lilly And Company Solid forms of 7-[[(1S)-1-[4-[(1S)-2-cyclopropyl-1-(4-prop-2-enoylpiperazin-1-yl)ethyl]phenyl]ethyl]amino]-1-ethyl-4H-pyrimido[4,5-d][1,3]oxazin-2-one

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018111707A1 (fr) 2016-12-16 2018-06-21 Eli Lilly And Company Composés de 7-phénylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one en tant qu'inhibiteurs d'idh1 et d'idh2 mutants

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109311863B (zh) 2016-06-06 2021-10-29 伊莱利利公司 突变型idh1抑制剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018111707A1 (fr) 2016-12-16 2018-06-21 Eli Lilly And Company Composés de 7-phénylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one en tant qu'inhibiteurs d'idh1 et d'idh2 mutants

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
"Remington: The Science and Practice of Pharmacy", 2006, LIPPINCOTT, WILLIAMS & WILKINS
BADUR MG ET AL., CELL REPORTS, vol. 25, 2018, pages 1680
BLOOMFIELD CD ET AL., BLOOD REVS., vol. 32, 2018, pages 416 - 425
CHOE S ET AL.: "Molecular mechanisms mediating relates following ivosidenib monotherapy in subjects with IDHI-mutant relapsed or refractory acute myeloid leukemia", 61ST AM. SOC. HEMATOL. (ASH) ANNUAL MEETING POSTER, 7 December 2019 (2019-12-07)
CHOE, S. ET AL., BLOOD ADV., vol. 4, no. 9, 2020, pages 1894 - 1905
CLARK, O. ET AL., CLIN. CANCER. RES., vol. 22, 2016, pages 1837 - 42
DOHNER H ET AL., BLOOD, vol. 129, 2017, pages 424 - 447
GULLER JL ET AL., J. MOL. DIAGN., vol. 12, 2010, pages 3 - 16
LEE HJ ET AL., ONCOTARGET, vol. 9, 2018, pages 924 - 936
LUTHA, R ET AL., HAEMATOLOGICA, vol. 99, 2014, pages 465 - 473
MEGIAS-VERICAT J ET AL., BLOOD LYMPH. CANCER: TARGETS AND THERAPY, vol. 9, 2019, pages 19 - 32
MIYATA S ET AL., SCIENTIFIC REPORTS, vol. 9, 2019, pages 9787
MOLENAAR RJ ET AL., ONCOGENE, vol. 37, 2018, pages 1949 - 1960
P. STAHL ET AL.: "HANDBOOK OF PHARMACEUTICAL SALTS: PROPERTIES, SELECTION AND USE", 2008, VCHA/WILEY-VCH
S.M. BERGE ET AL.: "Pharmaceutical Salts", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 66, no. 1, January 1977 (1977-01-01), XP002675560, DOI: 10.1002/jps.2600660104
SUNG CHOE, ET AL.: "Molecular mechanisms mediating relapse following ivosidenib monotherapy in patients with IDH1-mutant relapsed or refractory acute myeloid leukemia", November 2019 (2019-11-01), pages 1 - 16, XP055816208, Retrieved from the Internet <URL:https://www.servier.us/sites/default/files/2021-04/ASH19_IVO_relapse.pdf> [retrieved on 20210621] *
WANG H-Y ET AL., J. EXP. CLIN. CANCER RES., vol. 35, 2016, pages 86
YEUNG DT ET AL., PATHOLOGY, vol. 43, 2011, pages 566 - 579
ZIAI, JMAJ SIDDON, AM. J. CLIN. PATHOL, vol. 144, 2015, pages 539 - 554

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022020281A1 (fr) * 2020-07-20 2022-01-27 Eli Lilly And Company Polythérapie avec un inhibiteur d'idh1 mutant, un analogue de désoxyadénosine et un agent à base de platine
US11746115B2 (en) 2021-08-13 2023-09-05 Eli Lilly And Company Solid forms of 7-[[(1S)-1-[4-[(1S)-2-cyclopropyl-1-(4-prop-2-enoylpiperazin-1-yl)ethyl]phenyl]ethyl]amino]-1-ethyl-4H-pyrimido[4,5-d][1,3]oxazin-2-one

Also Published As

Publication number Publication date
AU2021241471A1 (en) 2022-09-29
CN115335059A (zh) 2022-11-11
AU2021241471B2 (en) 2023-12-14
JP7462789B2 (ja) 2024-04-05
JP2023518858A (ja) 2023-05-08
EP4125916A1 (fr) 2023-02-08
IL296094A (en) 2022-11-01
MX2022011846A (es) 2023-01-04
US20230071978A1 (en) 2023-03-09
BR112022017491A2 (pt) 2022-10-18
EP4125916B1 (fr) 2024-04-17
CA3172679A1 (fr) 2021-09-30
KR20220155379A (ko) 2022-11-22

Similar Documents

Publication Publication Date Title
Saha et al. Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma
Sheppard et al. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors
AU2021241471B2 (en) Method for treating IDH1 inhibitor-resistant subjects
US9889127B2 (en) Method of inhibiting mutant C-KIT
TW201412314A (zh) 抑制組成型活性磷酸化ｆｌｔ３激酶的方法
US20220313700A1 (en) Methods for treating map3k8 positive cancers
AU2021241470B2 (en) Combination therapy with a mutant IDH inhibitor and a Bcl-2 inhibitor
US10835525B2 (en) Method of inhibiting mutant C-KIT
Wasko et al. Tumor-selective activity of RAS-GTP inhibition in pancreatic cancer
Cross et al. BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features
Custodio et al. An in vitro and in vivo evaluation of the effect of relacorilant on the activity of cytochrome P450 drug metabolizing enzymes
Yonesaka et al. Dual blockade of EGFR tyrosine kinase using osimertinib and afatinib eradicates EGFR‑mutant Ba/F3 cells
Liu et al. The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer
EP4337217A1 (fr) Procédé de traitement de sujets résistants à l&#39;inhibiteur de l&#39;idh
CN115443137B (zh) 使用突变idh抑制剂和bcl-2抑制剂的组合疗法
US11642340B2 (en) Method of inhibiting mutant C-KIT
US20220184029A1 (en) Compositions and methods for treating neuroblastoma
Yonesaka et al. Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II Trial
Frank et al. Forward Genetic Screens Identify Mechanisms of Resistance to Small-Molecule Lactate Dehydrogenase Inhibitors
Yamada et al. Predictive and prognostic value of excision repair cross-complementing group 1 in patients with advanced gastric cancer
Sequero-Lopez et al. P53. 01 Clinical Application of NGS Technology. Therapeutic Possibilities and Future Perspectives
Stewart et al. KRAS genomic status predicts the sensitivity of ovarian cancer cells to decitabine Running Title: KRAS status predicts sensitivity to decitabine in ovarian cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21718411

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2021241471

Country of ref document: AU

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022017491

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 3172679

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2022557868

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2021241471

Country of ref document: AU

Date of ref document: 20210322

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112022017491

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20220831

ENP Entry into the national phase

Ref document number: 20227036322

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021718411

Country of ref document: EP

Effective date: 20221024